Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer On Reorganizing, M&A And Investing In Internal R&D

01 Aug 2018

• By Jessica Merrill

A pair of feet standing on a tarmac road with yellow arrow print pointing in three different directions for the concept of making decision at the crossroad.

Related Content

Payers Like Biosimilars, But Rebates Remain The Bottom Line (For Now)

29 Nov 2017

Keeping Track: US FDA Approvals For Tibsovo, Kisqali And Second Neupogen Biosimilar

23 Jul 2018

Pfizer Biosimilars And Anti-Infectives Get Higher Profile Under New Structure

11 Jul 2018

Pfizer's CEO Is Bullish On Rebate Changes That Could Power New Launches

31 Jul 2018

Pfizer's Essential Health Leadership On Why US Biosimilars Will Take Off – Eventually

11 Apr 2018

Related Companies

Pfizer Inc.

Johnson & Johnson

Novartis AG

Roche Holding AG

Eli Lilly and Company

Amgen, Inc.

Additional Topics

Biosimilars M & A Sales & Earnings Deals Commercial BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.